Back to Search Start Over

Cost-Effectiveness of a Cardiac Rehabilitation Program Specifically Designed for Patients With Obesity Within the OPTICARE XL Randomized Controlled Trial

Authors :
L.A. Visser
I. den Uijl
W.K. Redekop
M. Sunamura
M. Lenzen
E. Boersma
R.W.M. Brouwers
H.M.C. Kemps
H.J.G. van den Berg-Emons
N. ter Hoeve
Erasmus School of Health Policy & Management
Rehabilitation Medicine
Health Technology Assessment (HTA)
Cardiology
Source :
Archives of Physical Medicine and Rehabilitation, 104(6), 855-862. W.B. Saunders
Publication Year :
2023
Publisher :
W.B. Saunders, 2023.

Abstract

Objective: To assess the cost-effectiveness of a cardiac rehabilitation (CR) program specifically designed for cardiac patients with obesity vs standard CR. Design: Cost-effectiveness analysis based on observations in a randomized controlled trial. Setting: Three regional CR centers in the Netherlands. Participants: Cardiac patients (N=201) with obesity (BMI≥30 kg/m2) referred to CR. Interventions: Participants were randomized to a CR program specifically designed for patients with obesity (OPTICARE XL; N=102) or standard CR. OPTICARE XL included aerobic and strength exercise and behavioral coaching on diet and physical activity during 12 weeks, followed by a 9-month after-care program with “booster” educational sessions. Standard CR consisted of a 6- to 12-week aerobic exercise program, supplemented with cardiovascular lifestyle education. Main Outcome Measures: An economic evaluation, with an 18-month time horizon, in terms of quality-adjusted life years (QALYs) and costs from the societal perspective was performed. Costs were reported in 2020 Euros, discounted at a 4% annual rate, and health effects were discounted at a 1.5% annual rate. Results: OPTICARE XL CR and standard CR resulted in comparable health gain per patient (0.958 vs 0.965 QALYs, respectively; P=.96). Overall, OPTICARE XL CR saved costs (-€4542) compared with the standard CR group. The direct costs for OPTICARE XL CR were higher than for standard CR (€10,712 vs €9951), whereas indirect costs were lower (€51,789 vs €57,092), but these differences were not significant. Conclusions: This economic evaluation showed no differences between OPTICARE XL CR and standard CR in health effects and costs in cardiac patients with obesity.

Details

Language :
English
ISSN :
1532821X and 00039993
Volume :
104
Issue :
6
Database :
OpenAIRE
Journal :
Archives of Physical Medicine and Rehabilitation
Accession number :
edsair.doi.dedup.....b105c7614e9f10199b74b7416b8eedc8